Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-09-19
2006-09-19
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S389700
Reexamination Certificate
active
07109304
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
REFERENCES:
patent: 5798554 (1998-08-01), Grimaldi et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6653104 (2003-11-01), Goldenberg
patent: 2003/0133930 (2003-07-01), Goldenberg
patent: WO 00/74718 (2000-12-01), None
Cochlovius, Bjom, et al., Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells The American Association of Immunologists, 2000, 0022-1767/00.
Ek, Onur, et al., “Treatment of Human B-Cell Precursor Leukemia in SCID Mice by Using a Coombination of the Anti-CD19 Immunotoxin B43-PAP with the Standard Chemotherapeutic Drugs Vincristine, Methylprednisolone. and L-Asparaginase” Leukemia and Lymphoma, vol. 31, pp. 143-149, 1997.
Ghetie, Maria-Ana, et al., “Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin,” Blood, Mar. 1, 2001 vol. 97, No. 5.
Ghetie, Maria-Ana, et al. “Evaluation of Ricin A Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo Therapy” Cancer Research 48, 2610-2617, 1988.
Ghetie, Maria-Ana, et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells” 1997 by the National Academy of Sciences 0027-8424/97947509-6 Proc. Natl. Acad. Sci USA vol. 94, pg. 7509-7514.
Ghetie, Maria-Ana et al., The Antitumor Activity of an Anti-CD22 Immunotoxin in SCID Mice with Disseminated Daudi Lymphoma is Enhanced by Either an Anti-CD19 Antibody or an Anti-CD19 Immunotoxin, Blood, vol. 80, No. 9 Nov. 1, 1992, pp. 2315-2320.
Heckman, A. et al., “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody” Cancer Immunol Immunotherapy 1991 364-372.
MA, D., et al., “RadioImmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 Monoclonal antibodies” Leukemia 2002 16, 60-66 Nature Publishing Group.
Mitchell, Paul, et al., “Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies” Antibody Targeting CD19+ Leukemia Xenografts, pp. 1105-1112, The Journal of Nuclear Medicine, vol. 44, No. 7, Jul. 2003.
Majolino, Patti C., et al., “High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in maglignant lymphomas” European Journal of Haematology ISSN 0902-4441, 1993, 51:18-24.
Roguska, Michael A, et al., “Humanization of Murine Monoclonal Antibodies through Variable Domain Resurfacing” Proc. Natl. Acad. Sci USA vol. 91, pp. 969-973, Feb. 1994.
Rowland, A. J., t al., “Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates” Cancer Immunology Immunotherapy (1993) Austin Research Institute.
Shan, Daming, et al. “Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells,” Cancer Immunol Immunother (2000) 48:673-683.
Stone, Marvin J., “A Phase I Study of Bolus Versus Continuous Infusion of the Anti-CD19 Immunotoxin, IgG-HD37-dgA, In Patients with B-Cell Lymphoma” Blood, vol. 88, No. 4 (Aug. 15), 1996, pp. 1188-1197.
Uckun, Fatih, et al., “Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor” 3906 vol. 5, 3906-3913, Dec. 1999 Clinical Cancer Research.
Uckun, Fatih M., “Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins” Blood, vol. 71, No.1 (Jan.), 1988; pp. 13-29.
Uckun, Fatih M., “Effective Immunochemotherapy of CALLA Cu Human Pre-B Acute Lymphoblastic Leukemia in Mice With Severe Combined Immunodeficiency Using B43 (anti-CD19) Pokeweed Antiviral Protein Immunotoxin Plus Cyclophosphamide” Blood, vol. 79, No. 12 (Jun. 15), 1992 pp. 3116-3129.
Zola H., “Preparation and characterization of a Chimeric CD 19 Monoclonal Antibody” Immunology and Cell Biology (1991) 69, 411-422.
Pietersz, Geoffrey A., et al., “In vitro and in vivo antitumour activity of a chemeric anti-CD19 antibody” Cancer Immunol Immunother (1995) 41:53-60.
Goldenberg David M.
Hansen Hans J.
Qu Zhengxing
Crowder Chun
Faegre & Benson LLP
Gambel Phillip
Immunomedics Inc.
LandOfFree
Humanized anti-CD19 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CD19 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CD19 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615161